Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.54 |
| ▸ | KDR | P35968 | 11/20 | 0.54 |
| ▸ | MST1R | Q04912 | 7/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585968 | 0.95 | MET (0.58) | METKDRMST1RSRC | |
| SCHEMBL306293 | 0.92 | MET (0.57) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2282956 | 0.89 | MET (0.43) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2288140 | 0.88 | EGFR (0.42) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2282757 | 0.85 | MET (0.43) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2281482 | 0.85 | MET (0.49) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2670825 | 0.84 | MET (0.61) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2280939 | 0.84 | MET (0.44) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2284158 | 0.83 | MET (0.39) | METKDRMST1RNTRK1KIT | |
| SCHEMBL10254782 | 0.83 | MET (0.67) | METKDRMST1RNTRK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885MST1R 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.